← Leaderboards
Fabio Cohen Tucci
Epigen Biosciences, Inc.
$6,913,476
Attributed
$13,054,521
Total exposure
14
Grants
13
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.7M · FY2011–24$2M$1.5M$1M$500K$0
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
Funding mix
By agency
NIH$13,054,521 · 14
By mechanism
R44$8,671,698 · 3
R43$2,722,370 · 8
R41$1,252,065 · 2
R21$408,388 · 1
Top collaborators
- Alysson R. Muotri6 shared
- Kumar Sharma3 shared
- Michael J. Caplan2 shared
- Anil K Karihaloo2 shared
- Rohit Kohli2 shared
- Tony L Yaksh2 shared
- Kevin Bacon1 shared
- Insoo Bae1 shared
Most similar at Epigen Biosciences, Inc.
Same institution · by research overlap
- Satheesh B Ravula$2,140,663
- Kevin Bacon$149,473
Others in their field
Top investigators on “Lead”
- Sonia M Thomas · Research Triangle Institute$700,865,642
- Bambra Strokes · Ppd Development Lp$526,656,217
- Tracy L Nolen · Research Triangle Institute$474,487,152
- Charles Mattias Mountain · Association Of Universities For Research In Astronomy, Inc.$423,098,075
- David Heimbrook · Leidos Biomedical Research, Inc.$406,926,511
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$382,410,253
Research focus
LeadDoseAnimal ModelPharmaceutical PreparationsNovel TherapeuticsIn VitroIn VivoPropertyEpigenMeetingsSmall Business Innovation Research GrantSmall MoleculeProgramsMouse ModelPreventSeriesPharmacologyRattusBaseSafetyGrantFibrosisResponsePre-Clinical
Grant awards (25)
Candidate selection of a LPAR1 antagonist for therapeutic application in NASH$1,041,548
R44 · FY2024 · DK · contact PI
Candidate selection of a LPAR1 antagonist for therapeutic application in NASH$971,732
R44 · FY2023 · DK · contact PI
New Therapy for the Treatment of Primary Biliary Cholangitis.$448,110
R43 · FY2023 · DK · contact PI
Novel therapy for Fragile X syndrome$1,157,216
R44 · FY2022 · MH · contact PI
Novel therapy for Fragile X syndrome$998,958
R44 · FY2021 · MH · contact PI
Lead candidate identification of LPAR1 antagonists for therapeutic application in NASH$397,398
R43 · FY2021 · DK · contact PI
Administrative supplement for Novel therapy for Fragile X syndrome$50,000
R44 · FY2021 · MH · contact PI
Development of a novel therapeutic for the treatment of diabetic nephropathy and renal fibrosis$999,838
R44 · FY2020 · DK · contact PI
Assessment of a selective kinase inhibitor in pre-clinical models of NASH$375,033
R43 · FY2020 · DK · contact PI
Novel agents for idiopathic pulmonary fibrosis$299,983
R43 · FY2020 · HL · contact PI
Development of a novel therapeutic for the treatment of diabetic nephropathy and renal fibrosis$999,274
R44 · FY2019 · DK · contact PI
Development of a novel therapeutic for the treatment of diabetic nephropathy and renal fibrosis$999,500
R44 · FY2018 · DK · contact PI
Novel therapy for Fragile X syndrome$317,514
R41 · FY2018 · MH · contact PI
Assessment of LPA1R antagonists in animal models of NASH$298,946
R43 · FY2018 · DK · contact PI
Novel Treatment for Traumatic Brain Injury$417,267
R41 · FY2017 · NS
Novel therapy for Fragile X syndrome$399,938
R41 · FY2017 · MH · contact PI
Novel therapy for Fragile X syndrome$117,346
R41 · FY2017 · MH · contact PI
Development of novel agents for the treatment of renal fibrosis adminstrative supplement$2,000
R44 · FY2016 · DK · contact PI
Development of novel agents for the treatment of renal fibrosis$835,306
R44 · FY2015 · DK · contact PI
Development of novel agents for the treatment of renal fibrosis$616,326
R44 · FY2014 · DK · contact PI
Synthesis and evaluation of novel kinase inhibitors as anti-metastasis agents for$225,000
R43 · FY2014 · CA · contact PI
Novel anti-metastasis agents for triple negative breast cancer$288,297
R43 · FY2013 · CA · contact PI
Selective LPA1 receptor antagonists as agents in prevention of renal fibrosis$389,603
R43 · FY2012 · DK · contact PI
The role of selective brain penetrating GRPR antagonists in pruritis.$184,000
R21 · FY2012 · NS · contact PI
The role of selective brain penetrating GRPR antagonists in pruritis.$224,388
R21 · FY2011 · NS · contact PI